Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/38926
Title: A retrospective, multicentre study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium
Authors: Nasreddine, R.
Florence, E.
Yombi, J.
Henrard, S.
Darcis, G.
Van Praet, J.
Vandekerckhove, L.
Allard, S.
Demeester, R.
MESSIAEN, Peter 
Ausselet, N.
Delforge, M.
De Wit, S.
Issue Date: 2022
Publisher: JOHN WILEY & SONS LTD
Source: Journal of the International AIDS Society, 25 , p. 116 -117
Abstract: Conclusion • Several RCTs have demonstrated BIC/FTC/TAF to be a first-line option for treatment-naïve and experienced PLWH [1-4]. • Real-world studies provide complementary information to RCTs and ensure that those results can be generalized to broader populations seen in daily practice. • The aim of this study was to describe the Belgian HIV population treated with BIC/FTC/TAF and to evaluate its efficacy, durability, and tolerability in a real-world setting.
Document URI: http://hdl.handle.net/1942/38926
e-ISSN: 1758-2652
ISI #: 000870695800142
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
HIV Glasgow.pdf
  Restricted Access		Published version64.8 kBAdobe PDFView/Open    Request a copy
Show full item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.